Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12356457 | 0.96 | GPR119 (0.40) | GPR119MAPTLMNAKDM4ENPC1 | |
| SCHEMBL2245448 | 0.91 | GPR119 (0.40) | GPR119MAPTLMNAKDM4ENPC1 | |
| SCHEMBL2245181 | 0.91 | GPR119 (0.40) | GPR119MAPTLMNAKDM4ENPC1 | |
| SCHEMBL12356464 | 0.91 | GPR119 (0.40) | GPR119MAPTLMNAKDM4ENPC1 | |
| SCHEMBL12356463 | 0.89 | GPR119 (0.41) | GPR119MAPTLMNAKDM4ENPC1 | |
| SCHEMBL12356456 | 0.89 | GPR119 (0.40) | GPR119MAPTLMNAKDM4ENPC1 | |
| SCHEMBL12356454 | 0.89 | GPR119 (0.40) | GPR119MAPTLMNAKDM4ENPC1 | |
| SCHEMBL3401120 | 0.85 | GPR119 (0.39) | GPR119MAPTLMNAKDM4ENPC1 | |
| SCHEMBL2250155 | 0.83 | GPR119 (0.40) | GPR119MAPTLMNAKDM4ENPC1 | |
| SCHEMBL2249934 | 0.81 | GPR119 (0.43) | GPR119MAPTLMNAKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| WO-2009105717-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885MAPT 4009/4885LMNA 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.